Click here to get full coverage on Hims Breach Exposes the Most Sensitive Kinds of PHI - Dark Reading

Hims Breach Exposes the Most Sensitive Kinds of PHI  Dark Reading

Hims Breach Exposes the Most Sensitive Kinds of PHI - Dark Reading

Click here to get full coverage on Why Is HIMS Stock Down 40%? - Yahoo Finance

Why Is HIMS Stock Down 40%?  Yahoo Finance

Why Is HIMS Stock Down 40%? - Yahoo Finance

Click here to get full coverage on Hims & Hers price target slashed amid GLP-1 transition - Proactive financial news

Hims & Hers price target slashed amid GLP-1 transition  Proactive financial news

Hims & Hers price target slashed amid GLP-1 transition - Proactive financial news

Click here to get full coverage on Telehealth giant Hims & Hers says its customer support system was hacked - TechCrunch

Telehealth giant Hims & Hers says its customer support system was hacked  TechCrunch

Telehealth giant Hims & Hers says its customer support system was hacked - TechCrunch

Click here to get full coverage on Hims & Hers says limited data stolen in social engineering attack - Cybersecurity Dive

Hims & Hers says limited data stolen in social engineering attack  Cybersecurity Dive

Hims & Hers says limited data stolen in social engineering attack - Cybersecurity Dive

Click here to get full coverage on Hims & Hers warns of data breach after Zendesk support ticket breach - BleepingComputer

Hims & Hers warns of data breach after Zendesk support ticket breach  BleepingComputer

Hims & Hers warns of data breach after Zendesk support ticket breach - BleepingComputer

Click here to get full coverage on Hims & Hers (HIMS) Soars 57.4% on New Deal - Yahoo Finance

Hims & Hers (HIMS) Soars 57.4% on New Deal  Yahoo Finance

Hims & Hers (HIMS) Soars 57.4% on New Deal - Yahoo Finance

Click here to get full coverage on Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance - Yahoo Finance

Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance  Yahoo Finance

Why The Hims & Hers Health (HIMS) Story Is Resetting After Novo Deal And New Guidance - Yahoo Finance

Click here to get full coverage on Hims & Hers Health Is No Longer What The Market Thinks (NYSE:HIMS) - Seeking Alpha

Hims & Hers Health Is No Longer What The Market Thinks (NYSE:HIMS)  Seeking Alpha

Hims & Hers Health Is No Longer What The Market Thinks (NYSE:HIMS) - Seeking Alpha

Click here to get full coverage on Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Pullback? - simplywall.st

Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Pullback?  simplywall.st

Is It Time To Reassess Hims & Hers Health (HIMS) After The Recent Share Price Pullback? - simplywall.st

Click here to get full coverage on Why Is HIMS Stock Down 40%? - Trefis

Why Is HIMS Stock Down 40%? - Trefis

Click here to get full coverage on Hims & Hers expects to issue over 100,000 Wegovy prescriptions per month - medwatch.com

Hims & Hers expects to issue over 100,000 Wegovy prescriptions per month  medwatch.com

Hims & Hers expects to issue over 100,000 Wegovy prescriptions per month - medwatch.com

Click here to get full coverage on Novo Nordisk, Hims fall as Amazon adds Lilly GLP-1 pill - Investing.com

Novo Nordisk, Hims fall as Amazon adds Lilly GLP-1 pill  Investing.com

Novo Nordisk, Hims fall as Amazon adds Lilly GLP-1 pill - Investing.com

Click here to get full coverage on Hackers access names, contact information of some Hims customers - Modern Healthcare

Hackers access names, contact information of some Hims customers  Modern Healthcare

Hackers access names, contact information of some Hims customers - Modern Healthcare

Click here to get full coverage on Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - HIMS Investor Relations

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results  HIMS Investor Relations

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - HIMS Investor Relations

Click here to get full coverage on Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - Business Wire

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers  Business Wire

Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers - Business Wire

Click here to get full coverage on 2 Profitable Stocks with Exciting Potential and 1 We Ignore - StockStory

2 Profitable Stocks with Exciting Potential and 1 We Ignore  StockStory

2 Profitable Stocks with Exciting Potential and 1 We Ignore - StockStory

Click here to get full coverage on A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot - Yahoo Finance

A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot  Yahoo Finance

A Look At Hims & Hers (HIMS) Valuation After GLP 1 Crackdown And Wegovy Pivot - Yahoo Finance

Click here to get full coverage on Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration - simplywall.st

Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration  simplywall.st

Hims & Hers Health (HIMS) Is Down 6.1% After Expanding GLP-1 Access With Novo Nordisk Collaboration - simplywall.st

Click here to get full coverage on Hims & Hers Announces Strategic Shift for US Weight Loss Business - HIMS Investor Relations

Hims & Hers Announces Strategic Shift for US Weight Loss Business  HIMS Investor Relations

Hims & Hers Announces Strategic Shift for US Weight Loss Business - HIMS Investor Relations

Click here to get full coverage on BofA cuts Hims and Hers stock price target on EBITDA concerns - Investing.com

BofA cuts Hims and Hers stock price target on EBITDA concerns  Investing.com

BofA cuts Hims and Hers stock price target on EBITDA concerns - Investing.com

Click here to get full coverage on Hims & Hers price target slashed amid GLP-1 transition - Yahoo Finance

Hims & Hers price target slashed amid GLP-1 transition  Yahoo Finance

Hims & Hers price target slashed amid GLP-1 transition - Yahoo Finance

Click here to get full coverage on Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership - Has The Bull Case Changed? - Yahoo Finance

Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership - Has The Bull Case Changed?  Yahoo Finance

Hims & Hers Health (HIMS) Is Up 8.3% After Expanding Novo Nordisk GLP-1 Partnership And Launching New Weight-Loss Membership - Has The Bull Case Changed? - Yahoo Finance

Click here to get full coverage on Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6% - Yahoo Finance

Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6%  Yahoo Finance

Hims & Hers (HIMS) Taps Into $200-Billion Weight Loss Market, Soars 6% - Yahoo Finance

Click here to get full coverage on Hims & Hers Advances a Consumer-Centric Digital Health Platform - Yahoo Finance

Hims & Hers Advances a Consumer-Centric Digital Health Platform  Yahoo Finance

Hims & Hers Advances a Consumer-Centric Digital Health Platform - Yahoo Finance

Click here to get full coverage on HIMS Stock Jumps Premarket: CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce - Stocktwits

HIMS Stock Jumps Premarket: CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce  Stocktwits

HIMS Stock Jumps Premarket: CEO Targets 100K Monthly Wegovy Push After Novo Nordisk Truce - Stocktwits

Click here to get full coverage on Hims & Hers Names Kathryn Beiser as Chief Communications Officer - HIMS Investor Relations

Hims & Hers Names Kathryn Beiser as Chief Communications Officer  HIMS Investor Relations

Hims & Hers Names Kathryn Beiser as Chief Communications Officer - HIMS Investor Relations

Click here to get full coverage on Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path - simplywall.st

Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path  simplywall.st

Hims & Hers Health (HIMS) Valuation Check As Novo Nordisk GLP 1 Partnership Reopens Growth Path - simplywall.st

Click here to get full coverage on Okupe, Hims & Hers health CFO, sells $79k in shares - Investing.com

Okupe, Hims & Hers health CFO, sells $79k in shares  Investing.com

Okupe, Hims & Hers health CFO, sells $79k in shares - Investing.com

Click here to get full coverage on Hims & Hers Health stock falls as insider files to sell shares - Investing.com

Hims & Hers Health stock falls as insider files to sell shares  Investing.com

Hims & Hers Health stock falls as insider files to sell shares - Investing.com

Click here to get full coverage on Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform - HIMS Investor Relations

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform  HIMS Investor Relations

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform - HIMS Investor Relations

Click here to get full coverage on Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit - Yahoo Finance

Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit  Yahoo Finance

Hims & Hers Health (HIMS) Valuation After Novo Nordisk Weight Loss Deal And Product Exit - Yahoo Finance

Click here to get full coverage on Wegovy® Pill and Wegovy® Pen Now Available with Hims & Hers - Hims & Hers Newsroom

Wegovy® Pill and Wegovy® Pen Now Available with Hims & Hers  Hims & Hers Newsroom

Wegovy® Pill and Wegovy® Pen Now Available with Hims & Hers - Hims & Hers Newsroom

Click here to get full coverage on Why Is HIMS Stock Slipping Premarket Today? - Stocktwits

Why Is HIMS Stock Slipping Premarket Today?  Stocktwits

Why Is HIMS Stock Slipping Premarket Today? - Stocktwits

Click here to get full coverage on HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm  GlobeNewswire

HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire

Click here to get full coverage on Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy - HIMS Investor Relations

Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy  HIMS Investor Relations

Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy - HIMS Investor Relations

Click here to get full coverage on New Derivative Income ETFs Aren’t Worth the Risks - Barron's

New Derivative Income ETFs Aren’t Worth the Risks  Barron's

New Derivative Income ETFs Aren’t Worth the Risks - Barron's

Click here to get full coverage on Support platform breach exposes Hims & Hers customer data - Security Boulevard

Support platform breach exposes Hims & Hers customer data  Security Boulevard

Support platform breach exposes Hims & Hers customer data - Security Boulevard

Click here to get full coverage on Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results - HIMS Investor Relations

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results  HIMS Investor Relations

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results - HIMS Investor Relations

Click here to get full coverage on A New Era of Weight Management is Coming to Hims & Hers - Hims & Hers Newsroom

A New Era of Weight Management is Coming to Hims & Hers  Hims & Hers Newsroom

A New Era of Weight Management is Coming to Hims & Hers - Hims & Hers Newsroom

Click here to get full coverage on Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny - Infectious Disease Advisor

Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny  Infectious Disease Advisor

Hims Pulls Cheaper Wegovy Pill After Federal Scrutiny - Infectious Disease Advisor

Click here to get full coverage on Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 - HIMS Investor Relations

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026  HIMS Investor Relations

Hims & Hers to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 - HIMS Investor Relations

Click here to get full coverage on Novo, Hims reach deal to sell GLP-1 drugs together - BioPharma Dive

Novo, Hims reach deal to sell GLP-1 drugs together  BioPharma Dive

Novo, Hims reach deal to sell GLP-1 drugs together - BioPharma Dive

Click here to get full coverage on In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding - statnews.com

In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding  statnews.com

In earnings call, Hims CEO addresses scrutiny of GLP-1 compounding - statnews.com

Click here to get full coverage on Honest Hims hair growth review: What men should know before buying - USA Today

Honest Hims hair growth review: What men should know before buying  USA Today

Honest Hims hair growth review: What men should know before buying - USA Today

Click here to get full coverage on Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Yahoo Finance

Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?  Yahoo Finance

Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Yahoo Finance

Click here to get full coverage on US could take action including fines against Hims after brief Wegovy copy launch - Reuters

US could take action including fines against Hims after brief Wegovy copy launch  Reuters

US could take action including fines against Hims after brief Wegovy copy launch - Reuters

Click here to get full coverage on Hims & Hers shares rise as investors refocus on growth outlook despite recent data-breach disclosure - Quiver Quantitative

Hims & Hers shares rise as investors refocus on growth outlook despite recent data-breach disclosure  Quiver Quantitative

Hims & Hers shares rise as investors refocus on growth outlook despite recent data-breach disclosure - Quiver Quantitative

Click here to get full coverage on INSP vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance

INSP vs. HIMS: Which Stock Should Value Investors Buy Now?  Yahoo Finance

INSP vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance

Click here to get full coverage on Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales - statnews.com

Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales  statnews.com

Novo Nordisk, Hims reach deal to end bitter dispute over Wegovy sales - statnews.com

Click here to get full coverage on Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over - HIMS Investor Relations

Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over  HIMS Investor Relations

Hims & Hers Returns to the Big Game with a Message to All Americans: The Era of Health as a Luxury is Over - HIMS Investor Relations

Click here to get full coverage on Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com

Hims is in the crosshairs. Is a crackdown coming for compounding?  statnews.com

Hims is in the crosshairs. Is a crackdown coming for compounding? - statnews.com

Click here to get full coverage on Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office - HIMS Investor Relations

Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office  HIMS Investor Relations

Customers Say Care Through Hims & Hers Matches, or Beats, the Doctor’s Office - HIMS Investor Relations

Click here to get full coverage on Hims & Hers pulls copycat weight-loss pill after threats of legal action - CNBC

Hims & Hers pulls copycat weight-loss pill after threats of legal action  CNBC

Hims & Hers pulls copycat weight-loss pill after threats of legal action - CNBC

Click here to get full coverage on Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks - Yahoo Finance

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks  Yahoo Finance

Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks - Yahoo Finance

Click here to get full coverage on Hims and Novo Nordisk: Compounded Oral Semaglutide Pulled After Legal Challenge and HHS Pressure - Morningstar Canada

Hims and Novo Nordisk: Compounded Oral Semaglutide Pulled After Legal Challenge and HHS Pressure  Morningstar Canada

Hims and Novo Nordisk: Compounded Oral Semaglutide Pulled After Legal Challenge and HHS Pressure - Morningstar Canada

Click here to get full coverage on Hims & Hers says limited data stolen in social engineering attack - Yahoo Finance

Hims & Hers says limited data stolen in social engineering attack  Yahoo Finance

Hims & Hers says limited data stolen in social engineering attack - Yahoo Finance

Click here to get full coverage on Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025 - HIMS Investor Relations

Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025  HIMS Investor Relations

Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025 - HIMS Investor Relations

Click here to get full coverage on Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs - CNBC

Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs  CNBC

Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs - CNBC

Click here to get full coverage on Hims expansion may not come in time for risky GLP-1 business - Reuters

Hims expansion may not come in time for risky GLP-1 business  Reuters

Hims expansion may not come in time for risky GLP-1 business - Reuters

Click here to get full coverage on Novo Nordisk pops 7% after Hims & Hers pulls copycat Wegovy weight-loss pill - CNBC

Novo Nordisk pops 7% after Hims & Hers pulls copycat Wegovy weight-loss pill  CNBC

Novo Nordisk pops 7% after Hims & Hers pulls copycat Wegovy weight-loss pill - CNBC

Click here to get full coverage on Oral Semaglutide and the GLP-1 Compounding Reckoning: From Regulatory Ambiguity to FDA Enforcement, DOJ Referrals, and Novo Nordisk’s Case Against Hims & Hers - Buchanan Ingersoll & Rooney PC

Oral Semaglutide and the GLP-1 Compounding Reckoning: From Regulatory Ambiguity to FDA Enforcement, DOJ Referrals, and Novo Nordisk’s Case Against Hims & Hers  Buchanan Ingersoll & Rooney PC

Oral Semaglutide and the GLP-1 Compounding Reckoning: From Regulatory Ambiguity to FDA Enforcement, DOJ Referrals, and Novo Nordisk’s Case Against Hims & Hers - Buchanan Ingersoll & Rooney PC

Click here to get full coverage on Hers Brings Comprehensive Weight Loss Programme to the UK - HIMS Investor Relations

Hers Brings Comprehensive Weight Loss Programme to the UK  HIMS Investor Relations

Hers Brings Comprehensive Weight Loss Programme to the UK - HIMS Investor Relations

Click here to get full coverage on Hims & Hers will stop selling compounded version of Novo’s obesity pill - statnews.com

Hims & Hers will stop selling compounded version of Novo’s obesity pill  statnews.com

Hims & Hers will stop selling compounded version of Novo’s obesity pill - statnews.com

Click here to get full coverage on 3 Big Reasons to Love Hims & Hers Health (HIMS) - Yahoo Finance

3 Big Reasons to Love Hims & Hers Health (HIMS)  Yahoo Finance

3 Big Reasons to Love Hims & Hers Health (HIMS) - Yahoo Finance

Click here to get full coverage on 2 Profitable Stocks with Exciting Potential and 1 We Ignore - The Globe and Mail

2 Profitable Stocks with Exciting Potential and 1 We Ignore  The Globe and Mail

2 Profitable Stocks with Exciting Potential and 1 We Ignore - The Globe and Mail

Click here to get full coverage on Hims & Hers plans to acquire Eucalyptus for $1.15B - MobiHealthNews

Hims & Hers plans to acquire Eucalyptus for $1.15B  MobiHealthNews

Hims & Hers plans to acquire Eucalyptus for $1.15B - MobiHealthNews

Click here to get full coverage on Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding - Reuters

Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding  Reuters

HIMS

Price Chart

Key Statistics

Technicals

About HIMS

Latest News

Hims Breach Exposes the Most Sensitive Kinds of PHI - Dark Reading

Why Is HIMS Stock Down 40%? - Yahoo Finance

Hims & Hers price target slashed amid GLP-1 transition - Proactive financial news

Advanced Charts

Top Gainers

Top Losers